Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) announced that its clinical trial...
Simcere Halts R&D on Alzheimer’s Drug Candidates Amid Pipeline Setbacks
Simcere Pharmaceutical Group (HKG: 2096) has reportedly discontinued research and development of its Alzheimer’s disease...
Yifan Pharma Wins NMPA Approval for Norditropin Biosimilar Trial
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that it has received clinical trial approval...
GSK’s Linerixibat Accepted for EMA Review for Cholestatic Pruritus in PBC
UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the European Medicines Agency (EMA) has accepted the...
Sanofi’s Sarclisa Recommended for EU Approval in Newly Diagnosed Multiple Myeloma
France major Sanofi (NASDAQ: SNY) announced that the European Medicines Agency’s (EMA) Committee for Medicinal...
Beijing Tightens Price Risk Management for Scarce Medications
The Beijing Municipal Medical Insurance Bureau issued the “Notice on Further Strengthening Price Risk Management...
Cloudbreak Pharma’s IPO Raises HKD 522M for Ophthalmic Drug Development
Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of...
Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study
US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK/SYK...
Novo Nordisk’s Ozempic Gets Positive CHMP Opinion for Peripheral Artery Disease
Denmark-based Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency’s (EMA) Committee for...
Illumina to Acquire SomaLogic for $350M to Expand Proteomics Tech Integration
US major Illumina (NASDAQ: ILMN) announced plans to acquire SomaLogic, a leader in data-driven proteomics...
Denovo Biopharma Inks Licensing Deal With Chuang Yi for DB104 in Taiwan
Denovo Biopharma, a US-headquartered precision medicine company with significant operations in China, announced a licensing...
Hengrui Pharmaceuticals Wins NMPA Approval for Six Novel Solid Tumor Drugs
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clinical trial approvals from the...
Gan & Lee Pharmaceuticals Presents Phase II Results of GZR18 and GZR4 at ADA Scientific Sessions
China-based Gan & Lee Pharmaceuticals (SHA: 603087) presented multiple Phase II clinical outcomes for its...
EMA Panel Recommends Bio-Thera’s Usymro for Autoimmune Diseases
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
J&J’s Darzalex SC Recommended by CHMP for High-Risk Smoldering Multiple Myeloma
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended...
Eli Lilly’s Efsitora Meets Key Endpoints in Phase III Trials for Type 2 Diabetes
US major Eli Lilly and Company (NYSE: LLY) presented detailed results from the Phase III...
Johnson & Johnson’s Imbruvica Secures CHMP Recommendation for Expanded MCL Use
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that the Committee for Medicinal Products...
Bayer’s Nubeqa Receives Positive CHMP Opinion for mHSPC Treatment
German pharmaceutical giant Bayer AG (ETR: BAYN) announced last week that the European Medicines Agency...
Boao Lecheng Partners with China National Center for Neurological Diseases to Establish Translational Center
The Boao Lecheng International Medical Tourism Pilot Zone Administration announced last week a strategic cooperation...
Sichuan Huiyu’s CDCP1-Targeted ADC HY0001a Gets NMPA Clinical Trial Approval
China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) announced that it has received clinical trial...